Form 4: Revolution Medicines Executive Sells Shares for Tax Obligations Under Pre-Arranged Plan

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, Inc., sold 4,289 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Stephen Michael Kelsey, President, Research and Development at Revolution Medicines, Inc. (RVMD), reported a sale of common stock.
• On June 16, 2025, Mr. Kelsey disposed of 4,289 shares of RVMD common stock.
• The shares were sold at a weighted average price of $39.83 per share, with the actual price range being $39.6017 to $39.8291.
• This transaction was executed pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this transaction, Mr. Kelsey beneficially owns 289,414 shares of Revolution Medicines common stock.
• The beneficial ownership includes 94,426 RSUs and 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a sale of shares by an executive might initially seem negative, the context of it being a pre-planned transaction under a 10b5-1 plan for tax withholding purposes, combined with the executive's continued significant beneficial ownership and recent ESPP acquisition, indicates a routine event rather than a bearish signal about the company's prospects.

Positives

• The sale was pre-planned under a Rule 10b5-1 plan, indicating a routine, non-discretionary transaction rather than a reaction to new information.
• The executive acquired 652 shares through the Employee Stock Purchase Plan (ESPP) on May 31, 2025, demonstrating continued participation in company equity programs.
• The executive retains a significant beneficial ownership of 289,414 shares, including a substantial number of RSUs, aligning his interests with shareholders.

Negatives

• The transaction represents a reduction in the direct beneficial ownership of common stock by a key executive.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction. It does not provide information to analyze broader industry trends or competitors. Such transactions are common across all industries, particularly for executives managing their equity compensation and tax obligations.

Related Party Transactions

• The reported sale of common stock by Stephen Michael Kelsey, an officer of Revolution Medicines, Inc., is a related party transaction, specifically for tax withholding upon RSU vesting.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the pre-planned nature and tax-related purpose mitigate concerns. The executive's continued significant holdings align interests.
• Employees: No direct impact on employees mentioned.
• Customers: No direct impact on customers mentioned.
• Suppliers: No direct impact on suppliers mentioned.
• Creditors: No direct impact on creditors mentioned.

Next Steps

• The Reporting Person has undertaken to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the reported range.

Key Dates

Keywords

Revolution Medicines, RVMD, Stephen Michael Kelsey, Form 4, insider transaction, stock sale, executive compensation, Rule 10b5-1, RSU vesting, tax withholding